文献速递神经MR

FLAIR MRI的参数反应映射可早期提示胶质母细胞瘤进展风险

Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.
PubMed 文献 · Acad Radiol · 2020-09-11

研究对52例胶质母细胞瘤患者的纵向标准化FLAIR图像进行体素级参数反应映射(PRM),分析PRMrFLAIR+、PRMrFLAIR-和PRMrFLAIR0的体积分数。在26例按RANO标准为疾病稳定或部分缓解的亚组中,PRMrFLAIR+在第10至20周及连续评估中可分层无进展生存和总生存,而FLAIR体积变化无预测价值。结论认为PRMrFLAIR可能提供胶质母细胞瘤疾病进展的早期生物标志物。

要点

  • PRMrFLAIR+在第10周可分层PFS(p<0.01)和OS(p<0.001)。
  • 在26例RANO稳定或部分缓解者中,PRMrFLAIR+可分层第10至20周进展(PFS p<0.05;OS p=0.01),FLAIR体积变化无预测价值。
  • PRMrFLAIR+超过10%连续评估可在5.6个月分层PFA(p<0.0001),RANO标准至15.4个月才分层(p<0.0001)。

关键影像表现/征象

  • PRM将rFLAIR信号分为增加(PRMrFLAIR+)、降低(PRMrFLAIR-)或不变(PRMrFLAIR0)的体素体积分数。
  • 基于第10周RANO标准、FLAIR高信号体积相对变化和PRMrFLAIR+均可分层PFS和OS。

诊断标准与关键数值

  • 第10周RANO标准分层PFS(p<0.0001)和OS(p<0.0001)。
  • 第10周FLAIR高信号体积相对变化分层PFS(p=0.0011)和OS(p<0.0001)。
  • 第10周PRMrFLAIR+分层PFS(p<0.01)和OS(p<0.001)。
  • 第10至20周PRMrFLAIR+分层应答患者的进展(PFS p<0.05;OS p=0.01),而FLAIR体积测量变化无预测价值。
  • 连续评估中PRMrFLAIR+超过10%在5.6个月分层PFA(p<0.0001),RANO标准至15.4个月才分层(p<0.0001)。

临床应用与阅片要点

  • 原文结论认为PRMrFLAIR可能提供胶质母细胞瘤疾病进展的早期生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Glioblastoma image evaluation utilizes Magnetic Resonance Imaging contrast-enhanced, T1-weighted, and noncontrast T2-weighted fluid-attenuated inversion recovery (FLAIR) acquisitions. Disease progression assessment relies on changes in tumor diameter, which correlate poorly with survival. To improve treatment monitoring in glioblastoma, we investigated serial voxel-wise comparison of anatomically-aligned FLAIR signal as an early predictor of GBM progression.

MATERIALS AND METHODS: We analyzed longitudinal normalized FLAIR images (rFLAIR) from 52 subjects using voxel-wise Parametric Response Mapping (PRM) to monitor volume fractions of increased (PRMrFLAIR+), decreased (PRMrFLAIR-), or unchanged (PRMrFLAIR0) rFLAIR intensity. We determined response by rFLAIR between pretreatment and 10 weeks posttreatment. Risk of disease progression in a subset of subjects (N = 26) with stable disease or partial response as defined by Response Assessment in Neuro-Oncology (RANO) criteria was assessed by PRMrFLAIR between weeks 10 and 20 and continuously until the PRMrFLAIR+ exceeded a defined threshold. RANO defined criteria were compared with PRM-derived outcomes for tumor progression detection.

RESULTS: Patient stratification for progression-free survival (PFS) and overall survival (OS) was achieved at week 10 using RANO criteria (PFS: p <0.0001; OS: p <0.0001), relative change in FLAIR-hyperintense volume (PFS: p = 0.0011; OS: p <0.0001), and PRMrFLAIR+ (PFS: p <0.01; OS: p <0.001). PRMrFLAIR+ also stratified responding patients' progression between weeks 10 and 20 (PFS: p <0.05; OS: p = 0.01) while changes in FLAIR-volume measurements were not predictive. As a continuous evaluation, PRMrFLAIR+ exceeding 10% stratified patients for PFA after 5.6 months (p<0.0001), while RANO criteria did not stratify patients until 15.4 months (p <0.0001).

CONCLUSION: PRMrFLAIR may provide an early biomarker of disease progression in glioblastoma.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Hoff BA, Lemasson B, Chenevert TL, et al. Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma. Acad Radiol. 2020. PMID: 32928633. doi:10.1016/j.acra.2020.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。